BMJ Oncology · Published 2026-01-01 · DOI 10.1136/bmjonc-2025-001002
Circulating tumour DNA (ctDNA) offers a minimally invasive approach for early detection of cancer, monitoring molecular residual disease, assessing molecular response and identifying treatment resistance in advanced stages. Additionally, ctDNA enhances clinical decision-making by enabling real-time tumour assessment. This review highlights the growing role of liquid biopsy as a predictive and prognostic tool in non-small cell lung cancer management.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →